258 related articles for article (PubMed ID: 12769656)
1. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution.
Rivarola HW; Paglini-Oliva PA
Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun; 2(1):43-52. PubMed ID: 12769656
[TBL] [Abstract][Full Text] [Related]
2. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
3. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
4. The chemotherapy of chagas' disease: an overview.
Paulino M; Iribarne F; Dubin M; Aguilera-Morales S; Tapia O; Stoppani AO
Mini Rev Med Chem; 2005 May; 5(5):499-519. PubMed ID: 15892691
[TBL] [Abstract][Full Text] [Related]
5. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
6. Trypanothione reductase inhibitors: Overview of the action of thioridazine in different stages of Chagas disease.
Lo Presti MS; Bazán PC; Strauss M; Báez AL; Rivarola HW; Paglini-Oliva PA
Acta Trop; 2015 May; 145():79-87. PubMed ID: 25733492
[TBL] [Abstract][Full Text] [Related]
7. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives.
Rivera G; Bocanegra-García V; Ordaz-Pichardo C; Nogueda-Torres B; Monge A
Curr Med Chem; 2009; 16(25):3286-93. PubMed ID: 19548870
[TBL] [Abstract][Full Text] [Related]
9. In silico identification and evaluation of new Trypanosoma cruzi trypanothione reductase (TcTR) inhibitors obtained from natural products database of the Bahia semi-arid region (NatProDB).
da Paixão VG; Pita SSDR
Comput Biol Chem; 2019 Apr; 79():36-47. PubMed ID: 30710804
[TBL] [Abstract][Full Text] [Related]
10. Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds.
Jockers-Scherübl MC; Schirmer RH; Krauth-Siegel RL
Eur J Biochem; 1989 Mar; 180(2):267-72. PubMed ID: 2647489
[TBL] [Abstract][Full Text] [Related]
11. [Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
Gutierrez Correa J; Fairlamb AH; Stoppani AO
Rev Argent Microbiol; 2001; 33(1):36-46. PubMed ID: 11407019
[TBL] [Abstract][Full Text] [Related]
12. Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
Arias DG; Herrera FE; Garay AS; Rodrigues D; Forastieri PS; Luna LE; Bürgi MD; Prieto C; Iglesias AA; Cravero RM; Guerrero SA
Eur J Med Chem; 2017 Jan; 125():1088-1097. PubMed ID: 27810595
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulations of peptide inhibitors complexed with Trypanosoma cruzi trypanothione reductase.
Silva Da Rocha Pita S; Batista PR; Albuquerque MG; Pascutti PG
Chem Biol Drug Des; 2012 Oct; 80(4):561-71. PubMed ID: 22702225
[TBL] [Abstract][Full Text] [Related]
14. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
16. Relevance of Trypanothione Reductase Inhibitors on
Mendonça AAS; Coelho CM; Veloso MP; Caldas IS; Gonçalves RV; Teixeira AL; de Miranda AS; Novaes RD
Oxid Med Cell Longev; 2018; 2018():8676578. PubMed ID: 30473742
[TBL] [Abstract][Full Text] [Related]
17. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures.
Benson TJ; McKie JH; Garforth J; Borges A; Fairlamb AH; Douglas KT
Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):9-11. PubMed ID: 1355650
[TBL] [Abstract][Full Text] [Related]
18. Future prospects for the chemotherapy of Chagas' disease.
Fairlamb AH
Medicina (B Aires); 1999; 59 Suppl 2():179-87. PubMed ID: 10668262
[TBL] [Abstract][Full Text] [Related]
19. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines.
Khan MO; Austin SE; Chan C; Yin H; Marks D; Vaghjiani SN; Kendrick H; Yardley V; Croft SL; Douglas KT
J Med Chem; 2000 Aug; 43(16):3148-56. PubMed ID: 10956223
[TBL] [Abstract][Full Text] [Related]
20. A decade of targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):216-59. PubMed ID: 21824073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
